Michael Nonnenmacher is currently the Director Differentiating Technologies within the Product Line Drug Substance at Evonik Health Care. He has 15 years of experience in CMO business and fine chemical industry and a long track record in Pharmaceutical Process Development. One of his main research areas is the application of continuous processing to the development and manufacturing of APIs and intermediates. Michael holds a PhD in organic synthesis from the University of Heidelberg (Germany) and completed a PhD research fellowship at Texas A&M University, College Station, TX.